TQB2868 injection

TQB2868 · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TQB2868 injection, covering 2025-12-24 to 2025-12-24. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) [Phase 3]

See pricing